Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Piramal Pharma Limited

PPLPHARMA · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹238.91

+₹8.13 (+3.52%)(1D)

₹132.3052 Week Range₹240.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

42/100

Valuation

35/100

Quality

2/100

Growth

66/100

Health

50/100

Momentum

79/100

Valuation
35
Quality
2
Growth
66
Health
50
Momentum
79

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Piramal Pharma Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹238.91

Market cap

₹31,648 Cr

P/E ratio

Not available

P/B ratio

3.88

Dividend yield

Not available

ROE

Not available

RSI 14

73.17

1Y return

Not available

Piramal Pharma Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Piramal Pharma Limited (PPLPHARMA) stock page cover?

Piramal Pharma Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for PPLPHARMA?

Piramal Pharma Limited is currently shown with a delayed price near ₹238.91, P/E N/A.

Does the PPLPHARMA page provide investment advice?

No. The PPLPHARMA page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

WOCKPHARMA

Wockhardt Limited · Healthcare

EMCURE

Emcure Pharmaceuticals Limited · Healthcare

NEULANDLAB

Neuland Laboratories Limited · Healthcare

ROE vs ROCE

Compare return on equity and return on capital employed for Indian stock analysis. Learn how debt distorts shareholder ratios on Anvest.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Piramal Pharma Limited is an Indian pharmaceutical company specializing in contract development and manufacturing (CDMO) services, complex hospital generics, and consumer healthcare products. It operates globally, serving various markets with its diverse portfolio in the resilient healthcare sector.

Drug Manufacturers - Specialty & GenericGlobal FootprintFounded:2020CEO/MD:Peter DeYoungHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Revenue growth: -3.1%FY26 growth+7.8%3Y CAGR
EPS growth: N/M3Y CAGR

What Looks Strong

MarketShareholder returns have comfortably outpaced the Nifty 500 benchmark over the 3-year period.
TrendPrice momentum is strong, with the stock trading comfortably above its 200-day trend.

What to Watch

RevenueRevenue declined about 3% in FY26 (consolidated: ₹9,151 cr → ₹8,869 cr). Watch whether the next results confirm a trend or a one-off.
EarningsThe company reported a net loss in FY26 (consolidated) after a profit the prior year. Watch the return to profitability and its drivers.
MarginsOperating margin is thin at 1.0%, leaving limited buffer against input cost volatility. Watch gross margin and cost lines in the next results.

Reports a single operating segment in its results filings.
They leverage their manufacturing capabilities and R&D expertise to develop and supply pharmaceutical products and services.

FY26 (consolidated): revenue ₹8,869 cr, down 3% from ₹9,151 cr in FY25; a net loss of ₹326 cr, after a profit of ₹91.1 cr in FY25.
FY26 (consolidated): operating cash flow ₹1,653 cr; debt/equity 0.67×.
Latest quarter to Sep 2026 (consolidated): revenue ₹2,617 cr (up 28% year on year); net profit ₹5.0 cr.